



Cite this: *Mater. Adv.*, 2022, 3, 8684

## Epigallocatechin-gallate tailors the cell adhesivity of fibronectin coatings in oxidation and concentration-dependent manner

Beatrix Peter,<sup>1,2</sup> Nicolett Kanyo,<sup>3</sup> Inna Szekacs,<sup>1</sup> Antal Csimpai,<sup>3</sup> Szilvia Bosze<sup>1,2</sup> and Robert Horvath<sup>1</sup>

Fibronectin is an extracellular matrix component that plays a significant role in many physiological processes, such as cell adhesion, growth, differentiation, and migration. In this study, we revealed the interaction between this important protein and the widely studied natural active substance green tea polyphenol epigallocatechin-gallate (EGCG) and its oxidized form. Furthermore, we investigated the kinetics of cancer cell adhesion on the polyphenol-treated fibronectin coatings. We applied a high-throughput, label-free optical biosensor capable of monitoring the above processes in real time with an excellent signal-to-noise ratio. Our results show that EGCG and its oxidized form bind to fibronectin in a concentration-dependent manner and can form multilayers as well. Furthermore, both polyphenol forms inhibited cellular adhesion, however, the effect was more pronounced in the case of the oxidized form. The results were compared to the measurements performed on bare biosensor surfaces without fibronectin, and the roles of oxidation were investigated. It is suggested that the polyphenols can interact and block important cell adhesion protein motifs and affect the rigidity of the layers as well. Moreover, a novel molecular scale active mechanism involving the disulfide bridges of fibronectin was proposed to explain the recorded kinetic signals and highlight that these proteins can be active participants in the molecular scale transformations affecting adhesion.

Received 29th June 2022,  
Accepted 4th October 2022

DOI: 10.1039/d2ma00765g

rsc.li/materials-advances

## 1. Introduction

Fibronectin is a high-molecular-weight glycoprotein of the extracellular matrix that binds to integrin receptors.<sup>1–4</sup> It is a protein dimer, consisting of two monomers linked by a pair of C-terminal disulfide bonds.<sup>5</sup> It plays role in cell adhesion, growth, migration, differentiation, and migration. Furthermore, it is significant for processes like embryonic development and wound healing.<sup>1</sup> Fibronectin has RGD (Arg-Gly-Asp) and PHSRN (Pro-His-Ser-Arg-Asn) integrin-binding sequences. The RGD sequence mediates the interaction of fibronectin with integrins, while the PHSRN sequence modulates the interaction.<sup>6</sup> Integrin  $\alpha 5\beta 1$  was identified as a fibronectin-binding receptor in HeLa cells.<sup>7</sup> Integrins are not always active. Activation of an integrin

from the low to high ligand-binding affinity state requires conformational change due to cytoplasmic or extracellular interactions.<sup>8</sup> For example, activation of  $\alpha 5\beta 3$ ,  $\alpha IIb\beta 3$ ,  $\alpha 11$ , and  $\beta 1$  integrin receptors can be triggered by modifications of extracellular disulfide bonds (thiol-disulfide exchange).<sup>8</sup> Morphological alterations have been observed in tumors and cancer-derived cell lines; decreased fibronectin expression, increased fibronectin degradation, and/or decreased expression of integrin receptors, like the above-mentioned  $\alpha 5\beta 1$ .<sup>9</sup> According to the review article of Wang and Hielscher, it has been suggested that due to the interference with the processes of the immune system and engagement with several integrin receptors, fibronectin promotes cancer cell proliferation and survival.<sup>9</sup> Furthermore, its isoforms participate in tumorigenesis as well, thus different variants of fibronectin not just interact with cell surface receptors, but their interactions also activate signaling pathways for tumor growth.<sup>9</sup>

It has been shown that tumor cells produce an increased amount of ROS compared to normal tissue cells.<sup>10</sup> Thus cancer cells have enhanced ROS production upon cell–matrix interaction as well, so oxygen and ROS affect the production of ECM proteins at both transcriptional and (post)translational levels. This increased extracellular redox potential increases the

<sup>a</sup> Nanobiosensors Laboratory, Research Centre for Natural Sciences, Institute for Technical Physics and Materials Science, Konkoly-Thege u, 29-33, Budapest H-1120, Hungary. E-mail: peter.beatrix@ek-cer.hu

<sup>b</sup> Institute of Chemistry, Eötvös Loránd University, 112, POB 32, Budapest, H-1518, Hungary

<sup>c</sup> ELKH-ELTE Research Group of Peptide Chemistry, Eötvös Loránd Research Network (ELKH), Eötvös Loránd University, 112, POB 32, Budapest, H-1518, Hungary

<sup>d</sup> National Public Health Center, 1097, Budapest, Hungary



expression of cell adhesion molecules (P- and E-selectins, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)). This is important, because for example, in the case of leukocytes, this can generate inflammatory fibrosis. It has been suggested that the leg of the integrin  $\alpha$ -subunit contains cysteine residues, which are sensitive to oxidizing agents. ROS and other oxidizing agents can establish disulfide bridges, furthermore, prevent their formation when two vicinal disulfide bridges are oxidized to cysteine sulfenic acid groups. The head domain (including the  $\alpha$ -A-domain) contains several cysteine residues, but it does not seem to be affected by reducing agents or ROS. Furthermore, the mutation of cysteines within the A $\beta$ -domain of the  $\beta 3$  integrin subunit did not show any influence on the ligand-binding activity. Probably there are differences in the redox-regulation of EGF-domain-based cysteines between the two integrins  $\alpha 5\beta 3$  and  $\alpha 11b\beta 3$ , although they share the same  $\beta 3$  integrin subunit. Thus it seems that the  $\alpha$ -subunit influences the thiol-based redox regulation within the  $\beta$  integrin leg domains as well.<sup>10</sup>

The main compound of green tea, epigallocatechin-gallate, is probably the most studied polyphenol for decades.<sup>11–15</sup> A lot of studies showed its beneficial effects on human health, for instance, its anticancer, anti-inflammatory, and anti-metastatic activities.<sup>12,13,16–21</sup> These processes are in connection with cellular adhesion. Some experiments with cancer cell lines proved that this active substance effectively decreases adhesion to different extracellular matrix proteins like laminin,<sup>22</sup> fibronectin,<sup>4</sup> and collagen.<sup>23</sup> These results highlight the potential anticancer effect of EGCG.<sup>2,12,23,24</sup> Furthermore, EGCG has an impact on cancer cell viability as well. Our previous study showed that EGCG is cytostatic but not cytotoxic ( $IC_{50} > 500 \mu\text{g mL}^{-1}$ ) on HeLa cancer cells, as revealed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end-point assay (MTT) and flow cytometry.<sup>14</sup> Of note, an anticancer compound that is rather cytostatic than cytotoxic has distinct advantages in mainly affecting cancer cells. Often the main goal is not the direct killing of all cells (cytotoxicity), but rather inhibiting the proliferation of the cancer cells selectively (cytostatic activity).<sup>14</sup>

The dimerization of EGCG even under mild oxidative conditions has been extensively reviewed.<sup>12,13,15,25–27</sup> Tea polyphenols have antioxidant activities,<sup>26</sup> and EGCG is the most effective in reacting with reactive oxygen species (ROS).<sup>12,15</sup> These activities are due to the phenolic groups that are sensitive to oxidation and can generate quinone, an oxidized derivative of aromatic compounds.<sup>12,13</sup> Oxidation is an irreversible reaction, and the oxidation species were found to correspond to  $M_w + 14$  (where  $M_w$  is the molecular weight of EGCG), in which two hydrogen atoms are removed and one oxygen atom is added to the gallate moiety in the B-ring of EGCG.<sup>12,25</sup> When EGCG is oxidized in green tea, it forms two digallate dimers, theasinensin A ( $M_w$  914) and P2 ( $M_w$  884), finally theaflavin-3,3'-digallate ( $M_w$  868.7) when oxidized in black tea.<sup>12,26–29</sup>

In this work, we aimed to reveal the interaction between fibronectin and EGCG and its oxidized form with the subsequent cellular adhesion by using a label-free optical sensor device. For this purpose, we applied fibronectin-coated and bare sensor surfaces. The adsorbed mass and the number of formed EGCG

layers were also calculated from the recorded kinetic data. The presented sensor is sensitive to sub-nanometer scale changes in the cell membrane positioning or protein distribution while averaging the signals of thousands of adhering cells.<sup>30</sup> Both small molecules and the larger cells could be easily examined in the same experiment with very high resolution.<sup>30</sup> Furthermore, quantum-chemical modeling was used to reveal the molecular scale active mechanism and explain the recorded kinetic signals.

## 2. Materials and methods

All chemicals and reagents were obtained from Sigma-Aldrich Chemie GmbH, Munich, Germany unless stated otherwise.

### 2.1. Preparation of EGCG and oxidized EGCG solutions

The stock solution of EGCG was prepared freshly in assay buffer (20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) in Hank's balanced salt solution (HBSS), pH 7, hereafter HBSS-HEPES). The tested concentrations of the EGCG solution were 0.05, 0.5, 5, 20, 40, 50 and 500  $\mu\text{g mL}^{-1}$ . To get the oxidized EGCG forms, the freshly prepared solutions were subjected to heat treatment at 60–70 °C for 1.5 h in a water bath.<sup>30</sup>

### 2.2. Cell culture and cell adhesion assay buffer

HeLa cells (ECACC 93021013) were maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum (Biowest SAS, France), 4 mM L-glutamine, 0.25  $\mu\text{g mL}^{-1}$  amphotericin B, 100 U  $\text{mL}^{-1}$  penicillin and 100  $\mu\text{g mL}^{-1}$  streptomycin solution. Cells were cultured in a humidified incubator (37 °C, 5% CO<sub>2</sub>). On reaching 80% confluence, cells were detached every 3–4 days using 0.05% (w/v) trypsin and 0.02% (w/v) EDTA solution and were not used beyond passage 20.

### 2.3. The resonant waveguide grating (RWG) biosensor and related protocols for *in situ* monitoring the EGCG binding and cell adhesion

The Epic BenchTop (BT) system (Corning Incorporated, NY, USA) employed in this study is an RWG base optical biosensor with high-throughput microplate-based label-free detection, the method is described in earlier studies.<sup>30–33</sup> The experiments were run using 384-well uncoated biosensor microplates (5040, Corning) and 384-well fibronectin-coated plates (5042, Corning). During the experiments, the baseline with HBSS-HEPES buffer (30  $\mu\text{l}$ ) was recorded for approximately 40–60 min. After that, the buffer was removed from the wells. Then the EGCG solutions were pipetted (30  $\mu\text{l}$ ) into the wells and we measured them for approximately 80 min. Then washed 4 times, and the kinetic curves were recorded for 30 min again with HBSS-HEPES (30  $\mu\text{l}$ ). During this time, HeLa cells were brought into suspension by using trypsin-EDTA solution. trypsin-EDTA was removed before the complete detachment of HeLa cells and its activity was arrested by adding a complete culture medium. Harvested cells were centrifuged at 380  $\times g$  for 6 min and the cell pellet was resuspended in assay buffer. Cells were then counted in a hemocytometer, and 12 000 cells were added to each sensor well. The cells for buffer control received



assay buffer instead of cell suspension. All measurements were carried out in triplicate using three different wells at room temperature. Cell spreading was monitored until saturation of the biosensor signals (2 h). Averaging every 5 subsequent data points, the effective sampling rate was  $1/15\text{ s}^{-1}$ .<sup>30-33</sup>

#### 2.4. Quantumchemical modeling

A comparative modeling study on the binding of EGCG and its oxidized dimer form to fibronectin was performed using the Gaussian 09 program package.<sup>34</sup>

### 3. Results and discussion


The adsorption kinetics of EGCG and its oxidized form at various concentrations and the subsequent cell adhesion process was monitored online using a high-throughput RWG

biosensor. The measurement procedure and the typical kinetic curves obtained on fibronectin coating are shown in Fig. 1. The kinetic curves of the measurements with low ( $0.05\text{ }\mu\text{g ml}^{-1}$ ) and high concentrations ( $500\text{ }\mu\text{g ml}^{-1}$ ) of EGCG or oxidized EGCG exposure are shown. The biosensor measurements show that the (ox.) EGCG molecules irreversibly adsorbed on the fibronectin coating at higher concentrations (Fig. 1, bottom right).

We measured the adhesion processes of the cells on EGCG and oxidized EGCG-treated fibronectin coatings for two hours because during this period these types of cells can reach the total spread morphology.<sup>32</sup>

#### 3.1. Polyphenol adsorption and subsequent cellular adhesion on bare and fibronectin-coated surfaces

The effects of polyphenol exposure on fibronectin and the bare biosensor surface were investigated. The EGCG and its oxidized



**Fig. 1** Schematic illustration of the measurement procedure and the typical kinetic curves obtained on the fibronectin coating. Typical kinetic curves of the measurements; fibronectin treatment with low ( $0.05\text{ }\mu\text{g ml}^{-1}$ ) and high concentrations ( $500\text{ }\mu\text{g ml}^{-1}$ ) of EGCG or oxidized EGCG (denoted as '(ox.) EGCG' in this figure), and the subsequent cell adhesion kinetics on the treated coatings. On the left panel: typical sigmoidal cell adhesion kinetic curve (low concentration of (ox.) EGCG). The cells can easily spread on the coating. On the right panel: adsorption-like cell adhesion kinetic curves (high concentration of (ox.) EGCG). Cells cannot spread on the coating.



form adsorb on both surfaces in a concentration-dependent manner (Fig. 2 and 3A, E). A major amount adsorbed irreversibly and could not be removed by the washing procedure with buffer. The oxidized form adsorbs in a larger amount in all cases. On increasing the polyphenol concentration, the bound amount was also increased, but saturation was observed at a concentration of around  $20 \mu\text{g ml}^{-1}$  for EGCG on the bare surface (Fig. 2B). However, for oxidized EGCG, we get increasing data points (Fig. 2F), just like in the case of fibronectin coating and EGCG and its oxidized form (Fig. 3B and F). The adsorbed amount is different on the bare surface and the fibronectin coating; at  $500 \mu\text{g ml}^{-1}$  concentration the oxidized form adsorbed in almost two-fold amount to the fibronectin (Table 1). This proves that although (ox.) EGCG can adsorb on the bare surface irreversibly by physisorption, the polyphenol prefers binding to coatings, like fibronectin. Table 1 shows the exact adsorbed amount on bare and fibronectin surfaces.

For active receptor-mediated cell adhesion and spreading a sigmoid-like kinetic curve is observed on a non-treated fibronectin coating (Fig. 2C, G grey curve and Fig. 3C, G black curve), while the non-specific cell adhesion results in an adsorption-like kinetic curve on the polyphenol-treated and untreated bare biosensor surface (Fig. 2C and G). EGCG and its oxidized form inhibited cellular adhesion onto fibronectin in a concentration-dependent manner, and the effect of the oxidized form is more pronounced (Fig. 3C, D, G and H). Interestingly, the oxidized  $0.5 \mu\text{g ml}^{-1}$  EGCG may rather promote cellular adhesion compared to the non-oxidized form (Fig. 3C, D, G and H).

The highly hydrated poly(L-lysine)-graft-poly(ethylene glycol) (PLL-g-PEG) and its RGD (Arg-Gly-Asp) containing form, PLL-g-PEG-RGD (hereafter PP:PPR) employed in our previous work<sup>30</sup> can be considered only as a simplified model system.

The two interactions revealed previously are (i) the binding of EGCG and oxidized EGCG with H-bonds to the polymer and (ii) the effective blocking of the RGD adhesion motifs by the bound polyphenols. The concentration-dependent effects of EGCG and oxidized EGCG in the case of fibronectin suggest that the above-mentioned interactions play important roles in fibronectin, too.

However, analyzing the results deeper, some marked differences are also observed. Namely, the adhesion strengthening effect of the bound polyphenols at low concentrations is present, but much less dominant in fibronectin (see Fig. 3). We attribute this to the differences in conformational flexibility between the two systems, and effects of the cross-coupling of EGCG on this. Clearly, the PEG chains have relatively large conformational flexibility.

Moreover, it is quite revealing that in contrast to the polymer system at high oxidized EGCG concentrations cell adhesion does not completely diminish in fibronectin. But, interestingly, the cell adhesion decreasing effect of high EGCG concentration is approximately the same in the two systems (50%). Moreover, analyzing the relative effects in Fig. 4 some differences in the measured concentration range are also observed.

We analyzed the effect of EGCG oxidation by the subtraction of the EGCG normalized signal from the oxidized normalized

signal. These differences between fibronectin and the PP:PPR systems and their comparisons are plotted in Fig. 4A–E. The comparison of the different cell responses is also plotted in Fig. 4C and F.

These differences suggest the existence of other dominant interactions in fibronectin. Such interactions are mainly affecting the fibronectin-oxidized EGCG interactions in the middle and high concentration range and the fibronectin-EGCG interactions in the middle concentration range.

### 3.2. Calculation of surface adsorbed mass density from the RWG biosensor data

The adsorbed mass can be calculated from the RWG data. The wavelength shift [ $\Delta\lambda$  (pm)] can be converted to a surface-adsorbed mass ( $\text{ng cm}^{-2}$ ) by using the calibration equation of Orgovan *et al.*<sup>35</sup> This equation is valid for a polyelectrolyte solution with an RI increment of  $dn/dc = 0.1955 \text{ cm}^3 \text{ g}^{-1}$ .<sup>35</sup> The  $dn/dc$  value of the EGCG and oxidized EGCG solution is  $0.21 \text{ cm}^3 \text{ g}^{-1}$  as determined earlier by measuring the RI of the EGCG solutions using a tabletop refractometer.<sup>30</sup> Based on the previously developed methodology,<sup>33,35</sup> this value leads to the following calibration equation:

$$\Delta M = 0.2885 \text{ ng pm}^{-1} \text{ cm}^{-2} \times \Delta\lambda \quad (1)$$


where  $\Delta M$  is the surface-adsorbed EGCG and oxidized EGCG mass ( $\text{ng cm}^{-2}$ ) and  $\Delta\lambda$  is the measured wavelength shift (pm). These calculations are summarized in Table 1. The amount of polyphenol bound to the fibronectin coating was calculated by the method applied before.<sup>30</sup> First, the number of formed EGCG and oxidized EGCG (signed as 'ox.') layers can be easily calculated by taking the geometrical parameters of an EGCG molecule (approx. 1.4 nm in size) and its molecular weight ( $458.37 \text{ g mol}^{-1}$ ).<sup>30</sup>

### 3.3. Quantumchemical modeling and proposed molecular scale interactions

In our previous work,<sup>30</sup> we used a semiempirical quantum-chemical method and showed that EGCG binds to PEG chains by hydrogen bonds and the binding is stronger for the oxidative products of EGCG.<sup>30</sup> Regarding the dimer oxidative product of EGCG, we proposed a cross-coupling mechanism of polymer chains by the hydrogen-bonding network.<sup>30</sup> This effect might be present in fibronectin, too. Besides this, a novel interaction mechanism is also proposed involving cysteine residues of fibronectin. Cysteine-based redox modifications within integrin heterodimers might be subject to redox-dependent conformational changes of integrin.<sup>10</sup> This process can affect the binding activities and interactions of integrins and their exposed domains. Cell adhesion proteins, such as integrins, mediate the interaction of cells and other molecules and these interactions mainly depend on certain conformational status.


Of note, the performed theoretical modeling provided a plausible interpretation of redox transformation mediated by fibronectin-linked thiol/disulfide residue. To better emphasize the main interaction partners, the central residue of the EGCG dimer exclusively implicated in the critical multistep redox





**Fig. 2** The recorded kinetic curves when the bare biosensor surface was exposed to EGCG and oxidized EGCG solutions with various concentrations (A and E). The concentration dependence of the finally adsorbed amounts is shown separately (B and F). The biosensor signals were recorded after cell addition onto the polyphenol exposed coatings. For comparison, the cell spreading curves (recorded on the fibronectin coating) are also shown (C and G). The applied concentrations of EGCG and oxidized EGCG were 0, 0.05, 0.5, 5, 20, 40, 50, and 500  $\mu\text{g ml}^{-1}$ , as indicated in the graphs. The concentration dependence of the cell adhesion signals after 2 hours of cell addition (D and H).





**Fig. 3** The recorded kinetic curves when fibronectin was exposed to EGC and oxidized EGC solutions with various concentrations (A and E). The concentration dependence of the finally adsorbed amounts is shown separately (B and F). The biosensor signals were recorded after the addition of cells to the polyphenol exposed coatings. For comparison, the cell spreading curves (recorded on the fibronectin coating) are also shown (C and G). The applied concentrations of EGC and oxidized EGC were 0, 0.05, 0.5, 5, 20, 40, 50, and 500  $\mu\text{g ml}^{-1}$ , as indicated in the graphs. The concentration dependence of the cell adhesion signals after 2 hours of cell addition (D and H).

**Table 1** The raw biosensor data and the calculated adsorbed polyphenol mass on the surface for three different EGCG and oxidized EGCG (signed as 'ox.') concentrations, and the calculated number of formed polyphenol layers on the bare biosensor surface and fibronectin

Conc. ( $\mu\text{g ml}^{-1}$ )	Bare surface			Fibronectin		
	$\Delta\lambda$ (pm)	$\Delta M$ ( $\text{ng cm}^{-2}$ )	Number of layers	$\Delta\lambda$ (pm)	$\Delta M$ ( $\text{ng cm}^{-2}$ )	Number of layers
5	172.04	$49.63 \pm 3.31$	$1.31 \pm 0.08$	145.33	$41.93 \pm 0.66$	$1.11 \pm 0.02$
50	197.27	$56.91 \pm 4.52$	$1.51 \pm 0.12$	215.71	$62.23 \pm 0.64$	$1.65 \pm 0.02$
500	193.31	$55.76 \pm 1.59$	$1.47 \pm 0.04$	257.55	$74.30 \pm 1.10$	$1.97 \pm 0.03$
ox. 5	76.68	$22.17 \pm 2.98$	$0.58 \pm 0.08$	138.01	$39.82 \pm 1.16$	$1.05 \pm 0.03$
ox. 50	283.07	$81.66 \pm 3.32$	$2.16 \pm 0.09$	458.01	$132.13 \pm 2.07$	$3.49 \pm 0.05$
ox. 500	409.05	$118.01 \pm 3.30$	$3.12 \pm 0.09$	723.76	$208.80 \pm 6.84$	$5.52 \pm 0.18$

process is presented in red color in Fig. 5. For the sake of simplicity, the residual molecular fragments with complex structures on EGCG and fibronectin, not involved in the redox transformation, are replaced with methyl groups. This molecular fragment (central residue) is only involved in the redox transformation and was only subjected to theoretical modeling.

Under experimental conditions, both EGCG and integrin are targets of redox-based modifications. In our study we have highlighted redox-relevant aspects of the EGCG monomer-dimer and integrin system, that can affect integrin-layer-based cell adhesion dynamics.

A theoretical study was directed at modeling a thiol-mediated reductive cleavage of the dimeric terminal of EGCG. The modeling process was strictly focused on the exact molecular fragments that are involved in the crucial elementary reaction steps. It is assumed that under the *in vitro* experimental conditions this redox process involves two triphenol fragments of EGCG, the dimeric fragment of oxidized EGCG, and a cysteine-containing fibronectin segment that can form disulfide bridges. Accordingly, the methyl group on the simplified EGCG models is a simplified representation of the pending molecular fragments including long polyethylene glycol chains (which are not involved in the redox transformations), while MeSH and MeSSMe are the simplified representations of a cysteine side chain and a disulfide bridge, respectively, in the cysteine-enriched segment of fibronectin. We proposed a mechanism for the cysteine-mediated reductive cleavage of dimer EGCG (Fig. 5) and supported our view about the assumed reaction sequence by quantum chemical modeling carried out at the HF/3-21G\* level of theory<sup>36,37</sup> complemented with the IEFPCM solvent model<sup>38</sup> using the dielectric constant of water ( $\epsilon = 80.1$ ) to represent the biological environment. Focusing on the molecular regions involved in the actual reaction steps, in the course of calculation simplified structures (**1** and MeSH representing an EGCG dimer and the pending cysteine side chains, respectively, along with **6** and MeSSMe representing monomeric EGCG and protein/peptide disulfide bridges, respectively) were analyzed and subjected to modeling studies (Fig. 5).


Although transformation **1**  $\rightarrow$  **2** (its details are not presented) and the formation of the S-S bond leading to sulfonium-enolate (**3**  $\rightarrow$  **4**) are accompanied by significant increases in Gibbs free energy, the multistep reaction also comprises the hydrolytic double retro aldol process ( $2 + \text{H}_2\text{O} \rightarrow 2 \times 3$ ) followed by disulfide-elimination (**4**  $\rightarrow$  **5** + MeSSMe) and sequential 1,5 hydrogen shift in the resulting monomeric cyclohexadienone (**5**  $\rightarrow$  **6**), features favorable for overall thermodynamics

( $\Delta G = -11.96 \text{ kcal mol}^{-1}$ ). It must be noted here that in the course of thermodynamically unfavoured transformation **1**  $\rightarrow$  **2**, the feasible generation of the oxygen-bridged bis-thiosemicetal moiety is accompanied by a double conjugate thiol-addition on the enone residues that breaks down the stabilizing  $\pi$ - $\pi$  interaction in **1** as presented by HOMO-1 featuring marked electron density delocalized between the proximal C=C double bonds. On the other hand, the relatively large differences in the calculated energetics can at least partly be attributed to the use of a reasonably demanding calculation methodology optimizing the structures of **1**–**6** as separated species without any otherwise hardly predictable intermolecular interactions, *e.g.* the exact mode of solvation by definite numbers of water molecules. Utilizing intermolecular S<sup>+</sup>···O and O<sup>−</sup>···H interactions this solvent might significantly contribute to the stability of zwitterion **4** and transition state **TS(3–4)**, markedly increasing both the thermodynamic- and the kinetic feasibility of the crucial elementary step **3**  $\rightarrow$  **4** associated with the actual electron-transfer. Transition state **TS(3–4)** was localized as a saddle point on the potential energy surface by the QST2 method<sup>39</sup> connecting the local minima representing intermediates **3** and **4**. All calculations were performed using the Gaussian 09 software package.<sup>34</sup>

A simplified theoretical study was directed at modeling a thiol-mediated reductive cleavage of the dimeric terminal of EGCG. The modeling study was strictly focused on the molecular fragments that are involved in the crucial elementary steps. On the other hand, it is assumed that under the experimental conditions this redox process involves two triphenol fragments of EGCG, the dimeric fragment of oxidized EGCG and the cysteine-enriched fibronectin segment that is capable of forming disulfide bridges. Accordingly, the methyl group on the simplified EGCG models is the simplified representation of the pending molecular fragments including long polyethylene glycol chains, which are not involved in the redox transformation, while MeSH and MeSSMe are the simplified representations of a cysteine side chain and a disulfide bridge, respectively, in the cysteine-enriched segment of fibronectin.

Based on our quantum-chemical modeling, we can conclude that this redox process involves two triphenol fragments of EGCG, the dimeric fragment of oxidized EGCG and the cysteine-containing fibronectin segment that is capable of forming disulfide bridges. Furthermore, at lower EGCG concentrations, the oxidation process is slow, so there will likely be more dimers. At higher EGCG concentrations, the dimeric form immediately interacts with fibronectin (see Fig. 4A and B).






**Fig. 4** Effect of EGCG oxidation. The differences between the fibronectin and the PP:PPR systems and their comparison in terms of EGCG oxidation. (A) The difference in the normalized cell responses on fibronectin in the case of oxidized EGCG and EGCG (oxidized EGCG normalized signal minus EGCG normalized signal). (D) The difference in the response on fibronectin with oxidized EGCG and EGCG (oxidized EGCG normalized response endpoints minus EGCG normalized response endpoints). (B) The normalized differences in the cell response on PP:PPR the in case of oxidized EGCG and EGCG (oxidized EGCG signal minus EGCG signal). (E) The difference in the response on PP:PPR in the case of oxidized EGCG and EGCG (oxidized EGCG normalized response endpoints minus EGCG normalized response endpoints). (C) Comparison of the differences in cell response on fibronectin and PP:PPR coatings. (F) The relative difference in cell response on fibronectin and PP:PPR coatings (oxidized EGCG normalized response endpoints minus EGCG normalized response endpoints).

Overall, the presence of fibronectin shifts the balance to the monomer form. Therefore, the differences shown in Fig. 4C and F between the different cell adhesion signals of the oxidized and nonoxidized solutions might be explained. The difference between the effect of oxidized and nonoxidized solutions is less pronounced in fibronectin, especially at higher concentrations, perfectly in line with the described molecular scale mechanism.

It cannot be excluded that the disulfide bridges of fibronectin also play a role in the cell adhesive properties of the coatings. Of note, integrin activation by disulfide bond reduction was previously discovered.<sup>40</sup> Therefore, ligand accessibility on fibronectin might be affected by the formation of the disulfide bonds. Future

research is needed to more directly verify these interesting possibilities.

Cellular adhesion on fibronectin is an intensively researched field.<sup>2,3,9,41–43</sup> The role of various peptide sequences and glycosylation states of fibronectin concerning cellular adhesion was studied before, but the interaction of fibronectin with polyphenols in this relation was never investigated. It has been published that EGCG bind to fibronectin,<sup>44,45</sup> however, the adsorption kinetics of the oxidized solution and its effect on cellular adhesion remain uncovered. EGCG is unstable at high temperatures and under alkaline and neutral conditions ( $\text{pH} \geq 7$ ), and it dimerizes and oxidizes easily.<sup>12,26,46</sup> In an aqueous



**Fig. 5** EGCG monomer (reduced form) and EGCG dimer (oxidized form) using projective and stereochemical representation, respectively. The red-colored molecular fragment (central residue) is only involved in the redox transformation (A), only this part was subjected to theoretical modeling, the overall reaction is presented in part (B), for the sake of simplicity the residual molecular fragments with complex structures on EGCG and fibronectin, not involved in the redox transformation, are replaced for methyl groups. The proposed a mechanism for the cysteine-mediated reductive cleavage of dimer EGCG (C).



solution, it changes from non-colored to yellow in higher pH regions.<sup>12,25</sup> Although this is a relevant feature of this compound, the effect of the oxidized EGCG is poorly investigated.

## 4. Conclusions

In the present study, we examined the interaction between surface adsorbed fibronectin and EGCG and its oxidized form. Furthermore, the subsequent cellular adhesion on the coatings was real-time monitored using a high-throughput label-free optical biosensor. We employed both fibronectin-coated biosensor plates and bare sensor plates to quantify the differences between various circumstances.

Based on the recorded label-free data, we identified EGCG and oxidized EGCG multilayer formation onto fibronectin and bare surface as well. The number of EGCG and oxidized EGCG layers were calculated using the geometrical parameters of the EGCG molecule and its molecular weight.<sup>30</sup> As a result, at 500 µg ml<sup>-1</sup> EGCG, approximately 2 layers, while in the case of 500 µg ml<sup>-1</sup> oxidized EGCG, 5 layers were formed on the fibronectin coating. On the bare surface, 2 and 3 layers were adsorbed, respectively.

We proposed that the polyphenol molecules bound less between the fibronectin chains, and thus form fewer (approximately half) multilayers than in the case of PLL-g-PEG and PP:PPR coatings.<sup>30</sup> We suggest that at high concentrations the formed multilayers can effectively block RGD or PHSRN (or both) cell adhesion motifs, decreasing cell adhesion and spreading on the polyphenol-exposed protein films.

Moreover, a novel molecular scale mechanism involving the disulfide bridges of fibronectin was proposed to possibly explain the recorded kinetic signals and highlight that these proteins can be active participants in molecular scale transformations affecting adhesion, too. The disulfide bonds are key cross-links in proteins and they are reactive and can undergo bimolecular nucleophilic substitution, a reaction with free thiol resulting in thiol-disulfide exchange.<sup>47,48</sup> The function of some proteins is controlled by the cleavage of their disulfide bonds.<sup>49</sup> The interaction of the EGCG dimer at the molecular level with thiol-containing fibronectin was modelled. This modeling provided a plausible interpretation of the redox transformation mediated by fibronectin-linked thiol/disulfide residues. Future research is needed to more directly verify the exact contribution of this effect.

The introduced methodology could be further continued with other extracellular matrix proteins and other small molecule active substances, the method is capable of illuminating the most important features of EGCG-adhesion matrix interactions, highlighting the importance of ligand oxidation during cellular interactions.

## Author contributions

Beatrix Peter: investigation, data curation, writing – original draft, writing – review & editing, visualization, and funding

acquisition. Nicolett Kanyo: investigation. Inna Szekacs: investigation and writing – review & editing. Antal Csampai: modeling, interpretation of the redox system and writing – original draft. Szilvia Bosze: interpretation of the redox system and writing – original draft. Robert Horvath: conceptualization, project administration, supervision, writing – review & editing, and funding acquisition.

## Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgements

The present work was supported by the Hungarian Academy of Sciences [Lendület (Momentum) Program], the National Research, Development, and Innovation Office (NKFIH) [ERC\_HU, PD 131543 for B. P. and KKP\_19 Programs], and the Eötvös Loránd Research Network (ELKH). Project no. TKP2021-EGA-04 has been implemented with the support provided from the Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund, financed under the TKP2021 funding scheme.

## References

- 1 R. Pankov and M. Kenneth, *J. Cell Sci.*, 2002, **115**, 3861–3863.
- 2 M. Sazuka, T. Itoi, Y. Suzuki, S. Odani, T. Koide and M. Isemura, *Biosci., Biotechnol., Biochem.*, 1996, **60**, 1317–1319.
- 3 D. J. Iuliano, S. S. Saavedra and G. a Truskey, *J. Biomed. Mater. Res.*, 1993, **27**, 1103–1113.
- 4 Y. Suzuki and M. Isemura, *Biomed. Res.*, 2013, **34**, 301–308.
- 5 Y. Mao and J. E. Schwarzbauer, *Matrix Biol.*, 2005, **24**, 389–399.
- 6 K. Kimura, A. Hattori, Y. Usui, K. Kitazawa, M. Naganuma, K. Kawamoto, S. Teranishi, M. Nomizu and T. Nishida, *Invest. Ophthalmol. Visual Sci.*, 2007, **48**, 1110–1118.
- 7 J. Friedrichs, J. Helenius and D. J. Müller, *Proteomics*, 2010, **10**, 1455–1462.
- 8 M. Popielarski, H. Ponamarczuk, M. Stasiak, C. Watała and M. Świątkowska, *Am. J. Cancer Res.*, 2019, **9**, 1554–1582.
- 9 J. P. Wang and A. Hielscher, *J. Cancer*, 2017, **8**, 674–682.
- 10 J. A. Eble and F. F. De Rezende, *Antioxid. Redox Signaling*, 2014, **20**, 1977–1993.
- 11 B. Peter, J. Nador, K. Juhasz, A. Dobos, L. Korosi, I. Székács, D. Patko and R. Horvath, *J. Biomed. Opt.*, 2015, **20**, 067002.
- 12 B. Peter, S. Bosze and R. Horvath, *Eur. Biophys. J.*, 2017, **46**, 1–24.
- 13 B. N. Singh, S. Shankar and R. K. Srivastava, *Biochem. Pharmacol.*, 2011, **82**, 1807–1821.



14 B. Peter, R. Ungai-Salanki, B. Szabó, A. G. Nagy, I. Szekacs, S. Bösze and R. Horvath, *ACS Omega*, 2018, **3**, 3882–3891.

15 H. Tachibana, *Proc. Jpn. Acad., Ser. B*, 2011, **87**, 66–80.

16 R. C. C. de Pace, X. Liu, M. Sun, S. Nie, J. Zhang, Q. Cai, W. Gao, X. Pan, Z. Fan and S. Wang, *J. Liposome Res.*, 2013, **23**, 187–196.

17 P. T. Devika and P. Stanely Mainzen Prince, *Pharmacol. Res.*, 2008, **57**, 351–357.

18 D. S. Hsieh, H. Wang, S. W. Tan, Y. H. Huang, C. Y. Tsai, M. K. Yeh and C. J. Wu, *Biomaterials*, 2011, **32**, 7633–7640.

19 C.-F. Hung, T.-F. Huang, H.-S. Chiang and W.-B. Wu, *J. Cell. Biochem.*, 2005, **96**, 183–197.

20 T. Punathil, T. O. Tollefsbol and S. K. Katiyar, *Biochem. Biophys. Res. Commun.*, 2008, **375**, 162–167.

21 I. a Siddiqui, M. Asim, B. B. Hafeez, V. M. Adhami, R. S. Tarapore and H. Mukhtar, *FASEB J.*, 2011, **25**, 1198–1207.

22 Y. Suzuki and M. Isemura, *Cancer Lett.*, 2001, **173**, 15–20.

23 H. M. Lo, C. F. Hung, Y. Y. Huang and W. Bin Wu, *J. Biomed. Sci.*, 2007, **14**, 637–645.

24 D. Umeda, S. Yano, K. Yamada and H. Tachibana, *J. Biol. Chem.*, 2008, **283**, 3050–3058.

25 Y. Mizooku, M. Yoshikawa, T. Tsuneyoshi and R. Arakawa, *Rapid Commun. Mass Spectrom.*, 2003, **17**, 1915–1918.

26 J. Hong, H. Lu, X. Meng, H.-H. Colon, J. Ryu, Y. Hara and C. S. Yang, *Cancer Res.*, 2002, **62**, 7241–7246.

27 Z. Hou, S. Sang, H. You, M. J. Lee, J. Hong, K. V. Chin and C. S. Yang, *Cancer Res.*, 2005, **65**, 8049–8056.

28 J. Xu, Z. Xu and W. Zheng, *Molecules*, 2017, **22**, 1–18.

29 C. E. Isaacs, W. Xu, G. Merz, S. Hillier, L. Rohan and G. Y. Wen, *Antimicrob. Agents Chemother.*, 2011, **55**, 5646–5653.

30 B. Peter, E. Farkas, E. Forgacs, A. Saftics, B. Kovacs, S. Kurunczi, I. Szekacs, A. Csampai, S. Bosze and R. Horvath, *Sci. Rep.*, 2017, **7**, 42220.

31 I. Kurucz, B. Peter, A. Prosz, I. Szekacs, R. Horvath and A. Erdei, *Sens. Actuators, B*, 2017, **240**, 528–535.

32 N. Orgovan, B. Peter, S. Bösze, J. J. Ramsden, B. Szabó and R. Horvath, *Sci. Rep.*, 2014, **4**, 4034.

33 B. Peter, I. Lagzi, S. Teraji, H. Nakanishi, L. Cervenak, D. Zámbó, A. Deák, K. Molnár, M. Truszka and I. Szekacs, *ACS Appl. Mater. Interfaces*, 2018, **10**, 26841–26850.

34 M. J. Frisch, *et al.*, *Gaussian 09, Revision E.01*, Gaussian Inc., Wallingford CT, 2009.

35 N. Orgovan, B. Kovacs, E. Farkas, B. Szabó, N. Zaytseva, Y. Fang and R. Horvath, *Appl. Phys. Lett.*, 2014, **104**, 1–5.

36 C. Froese Fischer, *Comput. Phys. Commun.*, 1987, **43**, 355–365.

37 K. D. Dobbs and W. J. Hehre, *J. Comput. Chem.*, 1986, **7**, 359–378.

38 J. Tomasi, B. Mennucci and E. Cancès, *J. Mol. Struct.: THEOCHEM*, 1999, **464**, 211–226.

39 P. Chunyang and H. B. Schlegel, *Isr. J. Chem.*, 1993, **33**, 449–454.

40 B. Yan and J. W. Smith, *Biochemistry*, 2001, **40**, 8861–8867.

41 P. Speziale and G. Pietrocola, *Front. Microbiol.*, 2020, **11**, 1–13.

42 D. J. Vaca, A. Thibau, M. Schütz, P. Kraiczy, L. Happonen, J. Malmström and V. A. J. Kempf, *Med. Microbiol. Immunol.*, 2020, **209**, 277–299.

43 S. Y. Boateng, S. S. Lateef, W. Mosley, T. J. Hartman, L. Hanley and B. Russell, *Am. J. Physiol.: Cell Physiol.*, 2005, **288**, C30–C38.

44 C.-M. Chan, J.-H. Huang, H.-S. Chiang, W.-B. Wu, H.-H. Lin, J.-Y. Hong and C.-F. Hung, *Mol. Vis.*, 2010, **16**, 586–595.

45 E. Melgarejo, M. Á. Medina, F. Sánchez-Jiménez and J. L. Urdiales, *Br. J. Pharmacol.*, 2009, **158**, 1705–1712.

46 S. Hirun and P. D. Roach, *Int. Food Res. J.*, 2011, **18**, 1261–1264.

47 P. Carl, C. H. Kwok, G. Manderson, D. W. Speicher and D. E. Discher, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 1565–1570.

48 K. Kolšek, C. Aponte-Santamaría and F. Gräter, *Sci. Rep.*, 2017, **7**, 1–10.

49 P. J. Hogg, *Trends Biochem. Sci.*, 2003, **28**, 210–214.

